| Ezra Richard Singer, MD | |
|
223 N Frontage Road, Pearce, AZ 85625-0186 | |
| (520) 826-1088 | |
| (520) 826-1089 |
| Full Name | Ezra Richard Singer |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 223 N Frontage Road, Pearce, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932159399 | NPI | - | NPPES |
| 054388 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 20352 (Arizona) | Primary |
| Entity Name | Northern Cochise Community Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013060367 PECOS PAC ID: 4981514288 Enrollment ID: O20040727001399 |
News Archive
Tinnitus, migraine, epilepsy, depression, schizophrenia, Alzheimer's: all these are examples of diseases with neurological causes, the treatment and study of which is more and more frequently being carried out by means of magnetic stimulation of the brain. However, the method's precise mechanisms of action have not, as yet, been fully understood.
As scientists continue to search for effective antidotes to direct and indirect damage caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv* server demonstrates the potential of cannabinoid receptor agonists to alleviate myocardial damage in this condition even in the absence of any inhibitory effect on viral infection as such.
The Inc. 500, which ranks the fastest growing U.S. privately held companies, announced that DSG reached No. 82 in the nation, making it the fastest growing privately held company in the Philadelphia area. As an Inc. 500 honoree, DSG shares a prestigious pedigree with such notable companies as Intuit, Microsoft, and Oracle.
AIDS Healthcare Foundation (AHF) has urged Tibotec Pharmaceuticals Ltd., a division of Johnson & Johnson, to reconsider and reduce its steep price for its newest AIDS drug, etravirine (TMC 125), a non-nucleoside reverse transcriptase inhibitor, (NNRTI), which received Food and Drug Administration (FDA) approval on Friday after a fast track or 'priority review' and approval process granted to companies for medications and therapies intended to treat life-threatening illnesses such as AIDS.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ezra Richard Singer, MD Po Box 186, 223 N Frontage Road, Pearce, AZ 85625-0186 Ph: (520) 826-1088 | Ezra Richard Singer, MD 223 N Frontage Road, Pearce, AZ 85625-0186 Ph: (520) 826-1088 |
News Archive
Tinnitus, migraine, epilepsy, depression, schizophrenia, Alzheimer's: all these are examples of diseases with neurological causes, the treatment and study of which is more and more frequently being carried out by means of magnetic stimulation of the brain. However, the method's precise mechanisms of action have not, as yet, been fully understood.
As scientists continue to search for effective antidotes to direct and indirect damage caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv* server demonstrates the potential of cannabinoid receptor agonists to alleviate myocardial damage in this condition even in the absence of any inhibitory effect on viral infection as such.
The Inc. 500, which ranks the fastest growing U.S. privately held companies, announced that DSG reached No. 82 in the nation, making it the fastest growing privately held company in the Philadelphia area. As an Inc. 500 honoree, DSG shares a prestigious pedigree with such notable companies as Intuit, Microsoft, and Oracle.
AIDS Healthcare Foundation (AHF) has urged Tibotec Pharmaceuticals Ltd., a division of Johnson & Johnson, to reconsider and reduce its steep price for its newest AIDS drug, etravirine (TMC 125), a non-nucleoside reverse transcriptase inhibitor, (NNRTI), which received Food and Drug Administration (FDA) approval on Friday after a fast track or 'priority review' and approval process granted to companies for medications and therapies intended to treat life-threatening illnesses such as AIDS.
› Verified 2 days ago